BEDFORD, Mass. (AP) — BEDFORD, Mass. (AP) — Ocular Therapeutix Inc. (OCUL) on Monday reported a loss of $48.4 million in its fourth quarter.
On a per-share basis, the Bedford, Massachusetts-based company said it had a loss of 29 cents.
The results missed Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 24 cents per share.
The biotechnology company posted revenue of $17.1 million in the period, which beat Street forecasts. Three analysts surveyed by Zacks expected $16.7 million.
For the year, the company reported a loss of $193.5 million, or $1.22 per share. Revenue was reported as $63.7 million.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on OCUL at https://www.zacks.com/ap/OCUL
Copyright © 2025 The Associated Press. All rights reserved. This material may not be published, broadcast, written or redistributed.
